MyChesCo on MSN2h
FDA Approves GSK’s Blujepa as First New Oral Antibiotic for UTIs in 30 Years
The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...
GSK Wants UK to Open Up Health Records to Boost Drug Development
GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to ...
The Express Tribune3d
Deregulation boosts pharma profits by 210% YoY
Owing to deregulated prices, Pakistan's pharmaceutical sector witnessed a remarkable surge in profitability, posting a 210% ...
‘I’m not trying to turn GSK into Google’: How GSK’s Silicon Valley veteran has transformed the pharma giant into a tech powerhouse
For GSK’s Ramakrishnan, who has served as CDTO since 2021, the biggest challenge was helping her company get a head start in ...
The fall of 23andMe: How DNA testing lost its way
23andMe is a company on the ropes having filed for bankruptcy in the US. The one-time leader of the DNA analysis market – valued at $6 billion in 2021 – is now worth less than $50 million, a 99 ...
Barnard Castle Meet parade float to feature early locomotive
A locomotive-themed float, created by the Teesdale Railway History Group, will feature in the Barnard Castle Meet parade on Bank Holiday Monday, ...
Yahoo Finance24d
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Glaxo due for a pullback? Before we ...
Yahoo Finance24d
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
Will the recent positive trend continue leading up to its next earnings release, or is Glaxo due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take ...